Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in China
Client(s) Incyte Corporation
Jones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China. Incyte and Zai Lab will collaborate on the further development and commercialization of products containing this molecule for Mainland China, Hong Kong, Macau, and Taiwan, for hematology and oncology therapies for humans. Incyte will receive $17.5 million in up front fees, up to $60 million in milestone payments, and tiered royalties. Incyte has the option to co-promote such products in China.